TAC4 (NM_170685) Human Tagged ORF Clone

CAT#: RC212545L1

Lenti ORF clone of Human tachykinin 4 (hemokinin) (TAC4), transcript variant alpha, Myc-DDK-tagged

Specifications

Product Data

• Type: Human Tagged ORF Clone
• Tag: Myc-DDK
• Symbol: TAC4
• Synonyms: EK; HK-1; HK1; PPT-C
• Vector: pLenti-C-Myc-DDK
• E. coli Selection: Chloramphenicol (34 ug/mL)
• Mammalian Cell Selection: None
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC212545).
• Restriction Sites: SgfI-MluI Cloning Scheme for this gene
• ACCN: NM_170685
• ORF Size: 339 bp
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.

Reference Data

• RefSeq: NM_170685.2, NP_733786.2
• RefSeq Size: 675
• RefSeq ORF: 342
• Locus ID: 255061
• MW: 12.1 kDa
• Gene Summary: This gene is a member of the tachykinin family of neurotransmitter-encoding genes. Tachykinin proteins are cleaved into small, secreted peptides that activate members of a family of receptor proteins. The products of this gene preferentially activate tachykinin receptor 1, and are thought to regulate peripheral endocrine and paracrine functions including blood pressure, the immune system, and endocrine gland secretion. The products of this gene lack a dibasic cleavage site found in other tachykinin proteins. Consequently, the nature of the cleavage products generated in vivo remains to be determined. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]